Clozapine, agranulocytosis, and benign ethnic neutropenia
Author:
Open Access
- 1 September 2005
- journal article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 81 (959) , 545-546
Abstract
Clozapine is an atypical antipsychotic that is effective in treatment resistant schizophrenia.1 The National Institute for Health and Clinical Excellence (NICE) guidelines for schizophrenia specify that “in individuals with evidence of treatment resistant schizophrenia, clozapine should be introduced at the earliest opportunity”.2Keywords
This publication has 11 references indexed in Scilit:
- Racial Disparities in Antipsychotic Prescription Patterns for Patients With SchizophreniaAmerican Journal of Psychiatry, 2002
- Active monitoring of 12760 clozapine recipients in the UK and IrelandThe British Journal of Psychiatry, 1999
- Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patientsInternational Clinical Psychopharmacology, 1999
- Benign ethnic neutropenia: What is a normal absolute neutrophil count?Journal of Laboratory and Clinical Medicine, 1999
- Mechanism of Clozapine-Induced AgranulocytosisCNS Drugs, 1997
- Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and IrelandThe British Journal of Psychiatry, 1996
- Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United StatesNew England Journal of Medicine, 1993
- Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studiesPsychopharmacology, 1989
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988
- Benign familial leukopenia and neutropenia in different ethnic groupsEuropean Journal of Haematology, 1988